MODIFIZIERTE RNAI-MITTEL

Patent europeic · EP2880162 · En vigur

Inscripziun en il register

Numer da publicaziun
EP2880162
Numer da la dumonda
EP13747932
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
02-08-2013
Publitgà
10-06-2015
Concedì
05-07-2017
La protecziun finescha il pli tard
01-08-2033
Proxima taxa annuala scadenta
31-08-2027
Classas IPC
C12N 15/113 (2010.01)
C12N 15/11 (2006.01)
C07H 21/02 (2006.01)
Prioritad
US 201261679396 P 03.08.2012
US 201361791750 P 15.03.2013
Dumonda PCT
PCT/US2013/053346 02.08.2013
Publicaziun PCT
WO2014/022739 06.02.2014
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-09-2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. 01-09-2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 01.09.2025

  3. 01-09-2024

    Next annual fee due on

    Next annual fee due on
    31.08.2024 → 31.08.2025

    Published in Swissreg on 01.09.2024

  4. 01-09-2023

    Midada

    Published in Swissreg on 01.09.2023

  5. 06-09-2022

    Midada

    Published in Swissreg on 06.09.2022

  6. 05-07-2017

    Concedì

    Published in Swissreg on 05.07.2017

Partidas

Possessur

Alnylam Pharmaceuticals, Inc.

300 Third Street, 3rd Floor, Cambridge, MA 02142, US

Inventur

RAJEEV, Kallanthottathil, G.

Cambridge, MA 02142, US

MANOHANRAN, Muthiah

Cambridge, MA 02142, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.